You need to enable JavaScript in order to use the AI chatbot tool powered by ChatBot

About

News

Get the latest news from LifeNet Health LifeSciences.

 

BioTech Breakthrough Awards program

TruVivo Named Cell Biology Product of the Year

LOS ANGELES (Nov. 8, 2023) — TruVivo™, a pioneering all-human 2D+ hepatic system that supports ADME/DMPK, toxicology and disease modeling applications, has been selected as the Cell Biology Product of the Year in the second annual BioTech Breakthrough Awards program.

Read More

Partnership with CN Bio

LifeNet Health LifeSciences partners with CN Bio to set a new standard for cell quality and performance

Virginia Beach, Va. (Sept. 6, 2023) — Microphysiological systems hold the promise of revolutionizing compound discovery and safety testing — but only if researchers have access to high-quality, reliable 3D cells. LifeNet Health LifeSciences has been at the forefront of addressing this challenge, and recently the organization took another key step by entering into an agreement to supply and distribute hepatic cells to CN Bio, a leading organ-on-a-chip company that manufactures single- and multi-organ MPS platforms.

Read More

TruVivo, the first and only all-human 2D+ hepatic system

LifeNet Health LifeSciences launches TruVivo, a pioneering all-human 2D+ hepatic system, to revolutionize compound discovery

Virginia Beach, Va. (April 4, 2023) – LifeNet Health LifeSciences, the leader in all-human research solutions, today launched TruVivo, a pioneering all-human cell-based liver system, to support vital drug and compound development and discovery. TruVivo is the biggest co-culture advancement in more than a decade, offering stable, reliable results - well to well, experiment to experiment, and user to user.

Read More

New Cell-Based Assay Service for drug and compound discovery

LifeNet Health LifeSciences launches new, human-relevant Cell-Based Assay Service for drug and compound discovery

Virginia Beach, Va. (Aug. 1, 2022) - LifeNet Health LifeSciences, a leader in all-human biomedical research solutions, is launching a new Cell-Based Assay Service following the acquisition of biotechnology firm IONTOX. These new in vitro screening options offer alternatives to animal testing that support safer, more effective novel compound discovery – providing a new level of human relevance and predictability, while furthering LifeNet Health’s commitment to improve lives through the gift of donation.

Read More

LifeNet Health LifeSciences will showcase innovative all-human research solutions

LifeNet Health LifeSciences will showcase innovative all-human research solutions at SOT ToxExpo

Virginia Beach, Va.

Read More

Pure MHC, LLC announces collaboration with LifeNet Health

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

March 16, 2021

Austin, Texas, USA, March 16, 2021 -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Read More

LifeNet Health LifeSciences exhibits at 2021 Society of Toxicology ToxExpo

LifeNet Health LifeSciences highlights innovative human cell- and tissue-based solutions at 2021 Society of Toxicology ToxExpo

March 12, 2021

VIRGINIA BEACH, Va. (March 12, 2021) — LifeNet Health LifeSciences will showcase its portfolio of innovative human cell- and tissue-based research solutions — including the new, all-human Tri-Culture model, thyrocytes for use in 3D models and genotyped human hepatocytes — at the Society of Toxicology (SOT) virtual annual meeting and ToxExpo at booth #1322. LifeSciences provides researchers human-relevant research solutions to optimize outcomes and speed the drug discovery process.

Read More

Primary human lung cells to aid and accelerate efforts in COVID-19

LifeNet Health LifeSciences has isolated primary human lung cells to aid and accelerate efforts in COVID-19 drug development

February 3, 2021

VIRGINIA BEACH, Va. (Feb. 3, 2021) — LifeNet Health LifeSciences has successfully isolated three types of primary human lung epithelial cells from a single donor. One of the three types, alveolar epithelial type II cells, are of particular interest to scientists due to their applicability for respiratory disease research. LifeNet Health’s scientists have also isolated the bronchial and small airway epithelial cells, which are critical for the first lines of defense in protecting the lungs.

Read More

LifeNet Health launches newly expanded LifeSciences division

LifeNet Health launches newly expanded LifeSciences division with innovative solutions for researchers

January 13, 2021

VIRGINIA BEACH, Va.  — LifeNet Health announced today the launch of their newly expanded LifeSciences division which is offering human cell- and tissue-based research solutions through a new website, LNHLifeSciences.org.

Read More

LifeNet Health expands primary human liver cell offering

LifeNet Health strengthens its LifeSciences Division with Samsara Sciences asset acquisition

November 07, 2019

Virginia Beach, VA. - LifeNet Health, the world's leading provider of regenerative medicine solutions, has acquired the assets of Samsara Sciences, a San Diego-based life sciences company specializing in human primary liver and kidney cell isolation. The acquisition includes Samsara's equipment, inventory and associated technology.

Read More